Daiichi Sankyo Company ($DSKYF) announced an update on their ongoing clinical study. Study Overview: Substudy 06D, formally titled “A Phase 1/2 ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with Crohn’s disease treated with IV Entyvio demonstrated considerable improvements in ...

A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...

Electrocardiographic (ECG) assessment of patients with acute coronary syndromes (ACS) in the PLATO trial confirms that those receiving ticagrelor are more likely to experience ventricular pauses than ...

In patients with ST-segment elevation myocardial infarction (STEMI), early treatment with a pharmacoinvasive strategy is more often associated with aborted infarction than is primary percutaneous ...

In this video, Jia Luo, MD, highlighted a phase 2 randomized study in non-small cell lung cancer presented at ASCO Annual Meeting. “What was interesting was the patients were randomized to ...

August 29, 2010 (Stockholm, Sweden) — Two genetic substudies of the large pivotal trials of the new antiplatelet agents ticagrelor (Brilinta, AstraZeneca) and prasugrel (Effient, Lilly) confirm that ...

Company's host-directed therapeutic, EB05 (paridiprubart), demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory disease TORONTO, ON / ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ANAHEIM -- An ...

The virus, which is contagious and a common cause of respiratory illness, hospitalizes up to 160,000 people and is responsible for as many as 13,000 deaths in the United States every year. Pfizer’s ...